### UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

\_\_\_\_

#### FORM 8-K

# CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 21, 2012

(Exact Name of Registrant as Specified in Charter)  Delaware 001-33609 30-0520478  (State or Other Jurisdiction (Commission (IRS Employer of Incorporation) File Number) Identification No.)  4520 East-West Highway, Suite 300 20814	
(State or Other Jurisdiction (Commission (IRS Employer of Incorporation) File Number) Identification No.)  4520 East-West Highway, Suite 300 20814	
of Incorporation) File Number) Identification No.) 4520 East-West Highway, Suite 300 20814	
4520 East-West Highway, Suite 300 20814	
Bethesda, Maryland	
(Address of Principal Executive Offices) (Zip Code)	
(Former Name or Former Address, if Changed Since Last Report)	
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the	e
following provisions (see General Instruction A.2. below):	
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)	
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)	
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))	
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))	

# Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(b) Director Resignation

On September 21, 2012, Sucampo Pharmaceuticals, Inc. (the "Company") announced that Sachiko Kuno, Ph.D. was resigning from her positions as International Advisor – Business Development and a director of the Company, effective September 30, 2012.

#### SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SUCAMPO PHARMACEUTICALS, INC.

Date: September 21, 2012 By: /s/ THOMAS J. KNAPP

Name: Thomas J. Knapp

Title: Executive Vice President, Chief Legal

Officer & Corporate Secretary